Detalhe da pesquisa
1.
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Future Oncol
; 17(35): 4959-4969, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34783255
2.
User testing and performance evaluation of the Electronic Quality Improvement Platform for Plans and Pharmacies.
J Am Pharm Assoc (2003)
; 55(6): 634-641, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26547597
3.
Demographic differences in the treatment and control of glucose in type 2 diabetic patients: implications for health care practice.
Ethn Dis
; 22(1): 29-37, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22774306
4.
Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective.
J Comp Eff Res
; 7(8): 807-816, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29792516
5.
Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat.
Clinicoecon Outcomes Res
; 9: 629-639, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29066924
6.
The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA.
Pharmacoeconomics
; 33(7): 643-53, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25686799
7.
Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus.
J Diabetes Complications
; 25(3): 143-50, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20708416